Followers | 837 |
Posts | 120316 |
Boards Moderated | 18 |
Alias Born | 09/05/2002 |
![](https://investorshub.advfn.com/uicon/14742.png?cb=1465058685)
Sunday, September 26, 2010 11:57:30 PM
IDIX ReadMeFirst
[Updates:
2010-2011 news flow;
musings on FDA clinical hold of IDX184/IDX320;
bolus of 600K HCV patients awaiting treatment in US;
new version of “The New Battle Lines in HIV”;
new version of “HCV: Most Likely to Succeed.”]
What is IDIX’s business all about?
IDIX’s drug portfolio
Transcript of 2Q10 conference call
Valuation and finances
#msg-52659147 2Q10 financial results
#msg-52727319 Liquidity and cash usage
#msg-50505854 Thomas Weisel report with $9 target (4/23/10)
#msg-49743057 Milestone payments from GSK
#msg-35740500 Tyzeka royalty stream worth ~$25M
#msg-49569765 Latest financing transaction
#msg-49785732 Share count for valuation purposes
#msg-52570892 Musings on buyout vig
News flow
#msg-54847385 2010-2011 news flow
Officers, directors, and major shareholders
#msg-53320091 Composition of Board of Directors
#msg-48436375 Tamar Howson appointed to BoD (Mar 2010)
Capsule résumés of executive officers (click on a name)
#msg-37998991 NVS, IDIX revise terms of relationship
#msg-53641927 Largest shareholders include NVS and GSK
#msg-49785817 Chronology of NVS’ equity stake
#msg-53346061 Insider shareholdings and options
#msg-44704472 Recent insider transactions
HCV program: Economic rationale and competition
#msg-54841331 HCV: Most Likely to Succeed (IMHO)
#msg-38956178 HCV market forecast from Decision Resources
#msg-54346052 Bolus of 600K US patients awaiting treatment
#msg-34694166 US prevalence of genotypes 1a and 1b
#msg-40127105 Up-front payments of HCV partnerships
#msg-50280348 HCV treatment paradigms 2010-2017
#msg-54225312 Who’s Who in All-oral HCV Programs
#msg-36780163 Musings on combining drugs from different classes
#msg-30190435 Devastating risk of undertreating HCV
#msg-34925415 Interferon and the Law of Diminishing Returns
#msg-34797714 Annual sales of ifn-alpha drugs
HCV program: IDX184 nucleotide polymerase inhibitor
#msg-54120531 FDA puts clinical hold on IDX184 and IDX320
#msg-54130390 Musings on the FDA clinical hold
#msg-54120531 Final phase-2a data are very nice (scan to middle of PR)
#msg-49115388 Why nucleotides are better than nucleosides
#msg-39719159 Phase-1b monotherapy data
#msg-43046863 NVS declines to license IDX184
#msg-43102142 Musings on NVS’ decision (dewophile)
#msg-49116246 Possible IDX184 interest by Roche (1)
#msg-49123150 Possible IDX184 interest by Roche (2)
#msg-26915921 How IDX184 is unlike NM283
HCV program: IDX320 protease inhibitor
#msg-54120531 FDA puts clinical hold on IDX184 and IDX320
#msg-54130390 Musings on the FDA clinical hold (1)
#msg-54410072 Musings on the FDA clinical hold (2)
#msg-54120531 Final phase-1b monotherapy data (scan to middle of PR)
#msg-49055353 Phase-1 PK and drug-interaction data
#msg-36600884 Musings on selectivity of HCV PI’s
HCV program: IDX375 non-nucleoside polymerase inhibitor
#msg-54120531 Interim phase-1 data (scan to bottom)
#msg-34334563 Preclinical data from 2008 AASLD
HIV program
#msg-54833062 The New Battle Lines in HIV
#msg-52408979 Sustiva, which IDX899 might supersede, sells $1.3B/yr
#msg-35391933 IDIX, GSK ink IDX899 collaboration
#msg-52571933 Why investors tend to overlook IDX899
#msg-43254006 GSK/PFE launch ViiV Healthcare
#msg-49507158 IDIX receives $6.5M milestone from GSK (4/23/10)
#msg-49743057 Remaining IDX899 milestone payments from GSK
#msg-50765370 Design of phase-2b trials (scan to bottom)
#msg-48915175 How GSK is planning for a “nuke-sparing” trial
#msg-49282477 Why GSK is planning for a “nuke-sparing” trial
#msg-52730834 Phase-2b data for GSK’s ‘572 integrase inhibitor
#msg-37495719 Anticipated duration of a phase-2b trial
#msg-44790049 PK/food trial
#msg-31925486 Phase-1/2 IDX899 monotherapy data (PR)
#msg-31944395 Phase-1/2 IDX899 monotherapy data (chart)
#msg-46084532 IDX899 paper in Curr Opin Investigational Drugs
#msg-49275972 HIV market data from GILD’s 1Q10 CC
#msg-35674369 HIV market overview (2007 article from CNNMoney)
#msg-34894135 Musings on Truvada’s patent status
#msg-31175781 HIV incidence in US is higher than previously thought
#msg-31419107 Increased HIV screening will expand market
#msg-33124429 New guidelines to recommend earlier treatment (1)
#msg-36745396 New guidelines to recommend earlier treatment (2)
#msg-37210627 Half of untreated US carriers are in 350-500 CD4 range
#msg-29985830 Design of a late-stage HIV trial
Reference links
#msg-49716235 Overview of the HCV arena (from C&EN)
http://www.idenix.com/hepc/about
HCV drugs on market and in development
HIV drugs on market and in development
http://www.hivandhepatitis.com
[Updates:
2010-2011 news flow;
musings on FDA clinical hold of IDX184/IDX320;
bolus of 600K HCV patients awaiting treatment in US;
new version of “The New Battle Lines in HIV”;
new version of “HCV: Most Likely to Succeed.”]
What is IDIX’s business all about?
IDIX’s drug portfolio
Transcript of 2Q10 conference call
Valuation and finances
#msg-52659147 2Q10 financial results
#msg-52727319 Liquidity and cash usage
#msg-50505854 Thomas Weisel report with $9 target (4/23/10)
#msg-49743057 Milestone payments from GSK
#msg-35740500 Tyzeka royalty stream worth ~$25M
#msg-49569765 Latest financing transaction
#msg-49785732 Share count for valuation purposes
#msg-52570892 Musings on buyout vig
News flow
#msg-54847385 2010-2011 news flow
Officers, directors, and major shareholders
#msg-53320091 Composition of Board of Directors
#msg-48436375 Tamar Howson appointed to BoD (Mar 2010)
Capsule résumés of executive officers (click on a name)
#msg-37998991 NVS, IDIX revise terms of relationship
#msg-53641927 Largest shareholders include NVS and GSK
#msg-49785817 Chronology of NVS’ equity stake
#msg-53346061 Insider shareholdings and options
#msg-44704472 Recent insider transactions
HCV program: Economic rationale and competition
#msg-54841331 HCV: Most Likely to Succeed (IMHO)
#msg-38956178 HCV market forecast from Decision Resources
#msg-54346052 Bolus of 600K US patients awaiting treatment
#msg-34694166 US prevalence of genotypes 1a and 1b
#msg-40127105 Up-front payments of HCV partnerships
#msg-50280348 HCV treatment paradigms 2010-2017
#msg-54225312 Who’s Who in All-oral HCV Programs
#msg-36780163 Musings on combining drugs from different classes
#msg-30190435 Devastating risk of undertreating HCV
#msg-34925415 Interferon and the Law of Diminishing Returns
#msg-34797714 Annual sales of ifn-alpha drugs
HCV program: IDX184 nucleotide polymerase inhibitor
#msg-54120531 FDA puts clinical hold on IDX184 and IDX320
#msg-54130390 Musings on the FDA clinical hold
#msg-54120531 Final phase-2a data are very nice (scan to middle of PR)
#msg-49115388 Why nucleotides are better than nucleosides
#msg-39719159 Phase-1b monotherapy data
#msg-43046863 NVS declines to license IDX184
#msg-43102142 Musings on NVS’ decision (dewophile)
#msg-49116246 Possible IDX184 interest by Roche (1)
#msg-49123150 Possible IDX184 interest by Roche (2)
#msg-26915921 How IDX184 is unlike NM283
HCV program: IDX320 protease inhibitor
#msg-54120531 FDA puts clinical hold on IDX184 and IDX320
#msg-54130390 Musings on the FDA clinical hold (1)
#msg-54410072 Musings on the FDA clinical hold (2)
#msg-54120531 Final phase-1b monotherapy data (scan to middle of PR)
#msg-49055353 Phase-1 PK and drug-interaction data
#msg-36600884 Musings on selectivity of HCV PI’s
HCV program: IDX375 non-nucleoside polymerase inhibitor
#msg-54120531 Interim phase-1 data (scan to bottom)
#msg-34334563 Preclinical data from 2008 AASLD
HIV program
#msg-54833062 The New Battle Lines in HIV
#msg-52408979 Sustiva, which IDX899 might supersede, sells $1.3B/yr
#msg-35391933 IDIX, GSK ink IDX899 collaboration
#msg-52571933 Why investors tend to overlook IDX899
#msg-43254006 GSK/PFE launch ViiV Healthcare
#msg-49507158 IDIX receives $6.5M milestone from GSK (4/23/10)
#msg-49743057 Remaining IDX899 milestone payments from GSK
#msg-50765370 Design of phase-2b trials (scan to bottom)
#msg-48915175 How GSK is planning for a “nuke-sparing” trial
#msg-49282477 Why GSK is planning for a “nuke-sparing” trial
#msg-52730834 Phase-2b data for GSK’s ‘572 integrase inhibitor
#msg-37495719 Anticipated duration of a phase-2b trial
#msg-44790049 PK/food trial
#msg-31925486 Phase-1/2 IDX899 monotherapy data (PR)
#msg-31944395 Phase-1/2 IDX899 monotherapy data (chart)
#msg-46084532 IDX899 paper in Curr Opin Investigational Drugs
#msg-49275972 HIV market data from GILD’s 1Q10 CC
#msg-35674369 HIV market overview (2007 article from CNNMoney)
#msg-34894135 Musings on Truvada’s patent status
#msg-31175781 HIV incidence in US is higher than previously thought
#msg-31419107 Increased HIV screening will expand market
#msg-33124429 New guidelines to recommend earlier treatment (1)
#msg-36745396 New guidelines to recommend earlier treatment (2)
#msg-37210627 Half of untreated US carriers are in 350-500 CD4 range
#msg-29985830 Design of a late-stage HIV trial
Reference links
#msg-49716235 Overview of the HCV arena (from C&EN)
http://www.idenix.com/hepc/about
HCV drugs on market and in development
HIV drugs on market and in development
http://www.hivandhepatitis.com
“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”
Join the InvestorsHub Community
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.